GENMAB A/S -SP ADR (GMAB) Fundamental Analysis & Valuation

NASDAQ:GMAB • US3723032062

Current stock price

27.75 USD
+0.25 (+0.91%)
At close:
27.75 USD
0 (0%)
After Hours:

This GMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GMAB Profitability Analysis

1.1 Basic Checks

  • GMAB had positive earnings in the past year.
  • In the past year GMAB had a positive cash flow from operations.
  • Each year in the past 5 years GMAB has been profitable.
  • In the past 5 years GMAB always reported a positive cash flow from operatings.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 7.48%, GMAB belongs to the best of the industry, outperforming 92.46% of the companies in the same industry.
  • The Return On Equity of GMAB (16.47%) is better than 94.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 9.04%, GMAB belongs to the top of the industry, outperforming 92.84% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for GMAB is significantly below the industry average of 27.63%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • GMAB has a Profit Margin of 25.89%. This is amongst the best in the industry. GMAB outperforms 93.62% of its industry peers.
  • In the last couple of years the Profit Margin of GMAB has declined.
  • The Operating Margin of GMAB (33.60%) is better than 96.13% of its industry peers.
  • GMAB's Operating Margin has declined in the last couple of years.
  • GMAB has a better Gross Margin (93.60%) than 94.78% of its industry peers.
  • GMAB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GMAB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
  • GMAB has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
  • Compared to 1 year ago, GMAB has a worse debt to assets ratio.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.64 indicates that GMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GMAB has a Altman-Z score of 2.64. This is in the better half of the industry: GMAB outperforms 67.12% of its industry peers.
  • GMAB has a debt to FCF ratio of 4.80. This is a neutral value as GMAB would need 4.80 years to pay back of all of its debts.
  • GMAB has a better Debt to FCF ratio (4.80) than 91.68% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.88. This is a neutral value indicating GMAB is somewhat dependend on debt financing.
  • GMAB has a Debt to Equity ratio of 0.88. This is in the lower half of the industry: GMAB underperforms 74.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 2.64
ROIC/WACC1.44
WACC6.29%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • GMAB has a Current Ratio of 2.02. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.02, GMAB is not doing good in the industry: 76.79% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.01 indicates that GMAB has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.01, GMAB is not doing good in the industry: 75.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GMAB Growth Analysis

3.1 Past

  • The earnings per share for GMAB have decreased by -2.61% in the last year.
  • GMAB shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.47% yearly.
  • GMAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.25%.
  • The Revenue has been growing by 19.19% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%

3.2 Future

  • GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.88% yearly.
  • GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.86% yearly.
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue Next Year18.63%
Revenue Next 2Y16.71%
Revenue Next 3Y16.31%
Revenue Next 5Y12.86%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.86 indicates a correct valuation of GMAB.
  • Based on the Price/Earnings ratio, GMAB is valued cheaper than 94.97% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of GMAB to the average of the S&P500 Index (26.21), we can say GMAB is valued slightly cheaper.
  • Based on the Price/Forward Earnings ratio of 18.68, the valuation of GMAB can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 94.78% of the companies listed in the same industry.
  • GMAB's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.13.
Industry RankSector Rank
PE 15.86
Fwd PE 18.68
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 93.62% of the companies are valued more expensively.
  • GMAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.52% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.11
EV/EBITDA 15.63
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as GMAB's earnings are expected to grow with 17.95% in the coming years.
PEG (NY)N/A
PEG (5Y)1.67
EPS Next 2Y5.16%
EPS Next 3Y17.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMAB Dividend Analysis

5.1 Amount

  • No dividends for GMAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMAB Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/6/2026, 8:00:02 PM)

After market: 27.75 0 (0%)

27.75

+0.25 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners42.45%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.09B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts74.07
Price Target95.18 (242.99%)
Short Float %1.51%
Short Ratio5.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)6
Avg Revenue beat(8)225.98%
Revenue beat(12)10
Avg Revenue beat(12)350.6%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-34.37%
EPS NQ rev (3m)-56.09%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-15.77%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)0.85%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 15.86
Fwd PE 18.68
P/S 4.59
P/FCF 15.11
P/OCF 14.41
P/B 2.92
P/tB N/A
EV/EBITDA 15.63
EPS(TTM)1.75
EY6.31%
EPS(NY)1.49
Fwd EY5.35%
FCF(TTM)1.84
FCFY6.62%
OCF(TTM)1.93
OCFY6.94%
SpS6.04
BVpS9.5
TBVpS-5.9
PEG (NY)N/A
PEG (5Y)1.67
Graham Number19.34
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 2.64
F-Score4
WACC6.29%
ROIC/WACC1.44
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%
Revenue Next Year18.63%
Revenue Next 2Y16.71%
Revenue Next 3Y16.31%
Revenue Next 5Y12.86%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-1.15%
EBIT Next 3Y19.58%
EBIT Next 5Y4.81%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S -SP ADR / GMAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 6 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


What is the profitability of GMAB stock?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


What is the earnings growth outlook for GENMAB A/S -SP ADR?

The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -15.07% in the next year.